SCHEMBL4475156

SCHEMBL4475156

CC1CN(c2ccccc2CC2CCNC2=O)CC(C)N1C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER3 P43115 2/20 0.33
DPP4 P27487 1/20 0.32
DPP8 Q6V1X1 1/20 0.32
WDR5 P61964 1/20 0.32
GHSR Q92847 2/20 0.32
HTR1D P28221 3/20 0.32
HTR1B P28222 3/20 0.32
MC4R P32245 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
MAPT P10636 1/20 0.32
KMT2A Q03164 1/20 0.32
TAAR1 Q96RJ0 1/20 0.31
AR P10275 1/20 0.31
CHRM2 P08172 1/20 0.31
CHRM4 P08173 1/20 0.31
CHRM5 P08912 1/20 0.31
CHRM1 P11229 1/20 0.31
CHRM3 P20309 1/20 0.31
CXCR4 P61073 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5611262 0.82 NCF1 (0.46) MEN1LMNAMAPTKMT2A
SCHEMBL4732267 0.82 NCF1 (0.46) MEN1LMNAMAPTKMT2A
SCHEMBL1737562 0.82 NCF1 (0.46) MEN1LMNAMAPTKMT2A
SCHEMBL1740973 0.80 HTR1A (0.47) HTR1DHTR1B
SCHEMBL27686595 0.79
SCHEMBL4479843 0.79 HTR2C (0.37)
SCHEMBL4480301 0.79 NCF1 (0.54) MEN1LMNAMAPTKMT2A
SCHEMBL4474160 0.78 CHRNA7 (0.39) MEN1KMT2A
SCHEMBL4477924 0.76 NCF1 (0.47) MEN1LMNAMAPTKMT2A
SCHEMBL1740813 0.70 HTR1F (0.40) HTR1DHTR1BTAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7479559-B2 3-[-2-(Piperazin-1-yl)benzyl]pyrrolidin-2-one derivatives; antidepressants, anxiolytic agents; obsessive compulsive disorder, psychological disorders, phobias; 5-HT1 agonist or antagonists; side effect reduction, in particular cardiac QTc prolongation; hydrogenation PFIZER INC. (US) 2009-01-20 US disclosed
US-20050245521-A1 Novel benayl(idene)-lactam derivatives PFIZER INC. 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050245521-A1 Novel benayl(idene)-lactam derivatives HTR1E, HTR1D, HTR1A PTGER3 311/4885DPP4 2721/4885DPP8 2865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.